TOXICOKINETICS OF SULFASALAZINE (SALICYLazoSULFAPYRIDINE) AND ITS METABOLITES IN B6C3F1, MICE

WEI ZHENG, STEVEN M. WINTER, MICHAEL MAYERSOHN, JACK B. BISHOP, AND I. GLENN SIPES

Departments of Pharmacology & Toxicology (W.Z., S.M.W., I.G.S.) and Pharmaceutical Sciences (M.M.), University of Arizona; and National Institute of Environmental Health Sciences (J.B.B.)

(Received April 14, 1993; accepted July 7, 1993)

ABSTRACT:
The toxicokinetics of salicylazosulfapyridine (SASP) and its metabolites were investigated in male and female B6C3F1 mice either following single intravenous (5 mg/kg) or oral (67.5, 675, 1350, and 2700 mg/kg) doses, or following three consecutive daily oral doses (67.5, 1350, and 2700 mg/kg). Plasma concentrations of SASP and its metabolites were quantified by HPLC. Upon intravenous administration, SASP rapidly disappeared from blood with a mean residence time of 0.45–0.78 hr. The only metabolite of SASP found in plasma after an intravenous dose was sulfapyridine (SP). In both sexes, the absolute oral bioavailability of SASP ranged between 16.6–18.2% at a dose of 67.5 mg/kg, and between 2.6–8.7% at doses of 675–2700 mg/kg. Following oral administration of SASP, both SP and AcSP were identified in plasma. The area under the plasma concentration-time curves (AUC) of SP at all four oral doses were 21–32-fold or 5–25-fold greater than those of SASP in male or female mice, respectively. The acetylated form of SP and AcSP, produced AUC values higher than SASP but much less than SP. Multiple oral doses with SASP did not alter the temporal patterns of SASP absorption and elimination in comparison to a single dose. However, SP accumulated in both sexes following multiple oral doses. A gender-dependent difference in toxicokinetic profiles for SASP and SP was also observed. Female mice displayed a higher Cmax of SASP and SP than did male mice. Although the volume of distribution of SASP was similar in both sexes, the systemic clearance of SASP in males was about twice that observed in females. The results indicated that after SASP administration, the metabolites SP and AcSP displayed higher and more prolonged plasma concentration-time profiles than parent SASP. Therefore, SP may accumulate in the body following repeated dosing and contribute to the genotoxicity observed following administration of high doses of SASP.

SASP1 is the drug most widely prescribed for the treatment of inflammatory bowel diseases, such as ulcerative colitis, mild cases of regional enteritis, and granulomatous colitis (1–3). The drug is also being used as an alternative approach to treatment of rheumatoid arthritis (4–6). SASP is extensively metabolized by reductive cleavage of the azo-linkage in the gut to SP and 5-ASA (3). SP is well-absorbed and eventually excreted in the urine, but 5-ASA is poorly absorbed and mainly excreted in the feces (3). Although there has been extensive studies of the pharmacokinetics of SASP in humans, including patients with inflammatory bowel disease or rheumatoid arthritis (7–12), there have been few toxicokinetic studies performed in laboratory animals (13). The lack of such data limits the interpretation of the results of a variety of toxicological studies conducted in those species.

The possibility that SASP may induce DNA damage and chromosome aberrations in humans was indicated by cytogenetic studies of patients undergoing SASP therapy for inflammatory bowel diseases (14, 15, 17). In these studies, peripheral blood lymphocytes from SASP-treated individuals exhibited an increase in frequencies of both SCE and MN, compared with healthy, untreated controls (14, 15). Recent in vivo studies in B6C3F1 mice indicate that SASP significantly increases the frequencies of MN observed in erythrocytes obtained from peripheral blood or bone marrow (16). Through in vitro studies, it has been demonstrated that SASP itself can induce both SCE and MN. However, its metabolites, SP and acetylated SP, induce only SCE (17). It has been suggested that the in vivo metabolite responsible for SASP cytotoxicity is SASP hydroxylamine, which may account for these in vivo vs. in vitro differences (18).

Knowing the temporal patterns of the parent compound and its metabolites in the blood would help better define the mechanism(s) by which SASP and/or its metabolites induce mutagenic damage. However, there have been no toxicokinetic studies or identification of plasma metabolites in B6C3F1 mice, the animal model in which the extensive mutagenicity test data were obtained. Therefore, in this study, we have investigated the toxicokinetics of SASP and its metabolites following intravenous and oral administration of SASP to B6C3F1 mice. An important aspect of this study was determination of the time-dependency of the plasma concentrations of SASP and its metabolites at doses associated with the genotoxicity endpoint as studied by the National Toxicology Program (16).

Materials and Methods

Chemicals. Chemicals were obtained from the following sources: SASP (2-hydroxy-5-[(4-(2-pyridyl-aminosulfonyl)phenyl)azo]benzoic acid, CAS 599-79-1) from NTP Chemical Repository, Radaron Corporation (Research Triangle Park, NC); SP from Sigma Chemical Company (St.

1 Abbreviations used are: SASP, salicylazosulfapyridine; SP, sulfapyridine; 5-ASA, 5-aminosalicylic acid; SCE, sister chromatid exchange; MN, micronuclei; SPOH, 5-hydroxy-sulfapyridine; AsSPOH, N-acetylsulfopyridine; AcSP, N-acetyl sulfapyridine; Cmax, maximum plasma concentration; Tmax, time at which Cmax is achieved; K, first-order disposition rate constant; AUC, area under the plasma concentration-time curve; AU/M, total area under the first-minute curve; MRT, mean residence time; MAT, mean absorption (input) time; CLint, total body clearance; F, absolute oral bioavailability; Vd apparent volume of distribution.

Send reprint requests to: Dr. I. Glenn Sipes, Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ 85721.
Louis, MO); SPOH and AcSPOH from Kabi Pharmacia Therapeutics (Uppsala, Sweden); sodium phosphate (dibasic or monobasic) and methanol from Fisher Scientific Company (Fair Lawn, NJ). AcSP standard was synthesized by acetylation of SP with acetic anhydride and purified by recrystallization (19). The structure was confirmed by mass spectral analysis. All reagents used in this experiment were of analytical grade, HPLC grade, or the best available pharmaceutical grade.

Animals. Male and female B6C3F, mice (24 ± 3 g) were supplied by the National Institute of Environmental Health Sciences (Research Triangle Park, NC). At the time of use the mice were 8–10 weeks old. Upon arrival at the University of Arizona, the mice were kept in a temperature-controlled, 12-hr light/dark cycle facility, and acclimated for 1 week prior to experimentation. They were allowed tap water and food (Teklad mouse diet) ad libitum. Animals were fasted for 12 hr prior to administration of SASP.

Administration of SASP. SASP in corn oil was administered orally by gavage to groups of mice at doses of 67.5, 67.5, 1,350 and 2,700 mg/kg. For the multiple-dose study, mice were given daily oral doses (67.5, 1,350, and 2,700 mg/kg) at the same time of the day for three consecutive days. In an intravenous dose study, SASP was dissolved in distilled-deionized water (pH 9–10, adjusted with 5 N NaOH) and administered via the tail vein at a dose of 5.0 mg/kg (0.2–0.3 ml/mouse) over ~5–10 sec.

Collection of Blood Samples. At the appropriate times, the mice were subjected to euthanasia with CO2. Blood samples were collected from the inferior vena cava into heparinized syringes prior to (0 hr) and at 0.25, 0.5, 1, 2, 3, 4, 6, 8, and 12 hr following intravenous SASP administration and 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hr following oral administration. The experimental design allowed for 4–7 mice at each time. The blood was centrifuged at 5,000g for 5 min, and the plasma was transferred to an Eppendorf tube and stored at ~20°C until analyzed. The samples were usually processed within 3 days.

Sample Analysis. The plasma samples (0.15 ml) were mixed with 2 volumes of methanol and allowed to stand in an ice bath for 15 min to precipitate proteins. After centrifugation at 13,000g at 4°C for 15 min, an aliquot (20 μl) of the supernatant was analyzed by HPLC. SASP and its metabolites were separated and quantified on a 25 cm × 4.6 mm (i.d.) reversed-phase column (Ultracarb, C18, 7 μm) purchased from Phenomenex (Torrance, CA). Mobile system 1, used for SASP analysis, consisted of methanol and 25 mM (pH 2.5) phosphate buffer in a ratio of 64:36 (v/v) (20). Separations were performed at room temperature at a rate of 1 ml/min. Mobile system 2, used for analysis of SP, AcSPOH, SPOH, and AcSPOH, was composed of methanol and 20 mM (pH 7.0) phosphate buffer (20:80, v/v). The flow rate was 2 ml/min. A Spectra-Physics model 100 UV detector was used for detection of SASP and its metabolites. Wavelengths of 360 and 254 nm were used for detection of SASP and the metabolites, respectively. A typical HPLC chromogram is illustrated in fig. 1. The detection limit in plasma for SASP was 0.32 nmol/ml for SP, 0.5 nmol/ml; and for AcSP, 1.0 nmol/ml. For all compounds at 50 mmol/ml of plasma, the coefficient of variation was less than ±5% for intraday analyses and less than ±10% for interday analyses.

Toxicokinetic Analysis. Plasma concentration-time data were analyzed by noncompartmental methods. Values of $C_{max}$ and $T_{max}$ were obtained directly from plasma concentration-time profiles. The apparent $K$ was estimated by linear least squares regression of the data in the terminal phase. From these values, the half-lives were calculated ($t_\alpha = 0.693/K$). AUC and UMC were calculated using the linear trapezoidal rule and extrapolating to time infinity. For multiple doses, the steady-state AUC (0–24 hr) was used. MRT and MAT were calculated as follows:

$$MRT_{SASP} = \frac{AUC_{SASP}}{\text{AUC}}$$

$$MAT_{SASP} = \frac{AUC_{SASP}}{\text{AUC}} - MRT_{SASP}$$

$$MRT_{AcSPOH} = \frac{AUC_{AcSPOH}}{\text{AUC}_{SP, \text{sum}}} - \frac{AUC_{SASP}}{\text{AUC}_{SASP}}$$

$$\text{Fig. 1. HPLC chromatogram of SASP and its metabolites in B6C3F, mouse plasma.}$$

(A) HPLC system 1: 25 mM (pH 2.5) phosphate buffer:methanol (36:64), λ360nm; SASP, 20 μM. (B) HPLC system 2: 20 mM (pH 7.0) phosphate buffer:methanol (80:20), λ254nm; SPOH, 100 μM; SP, 100 μM; AcSPOH, 100 μM, and AcSP, 100 μM.

Equation 3 provides an estimate of the MRT of SP that is formed following the administration of its precursor, SASP (21). The systemic $CL_{tot}$ was computed by dividing the intravenous dose by AUC. $F$ for SASP was estimated from the ratio of $AUC_{tot}/AUC_{p}$ and corrected for differences in doses. $V_s$ was calculated from the following relationship,

$$\frac{V_s}{CL_{tot}} = \frac{CL_{tot}}{K}$$

All data are presented as mean ± SE. Statistical analysis for comparison of two means was performed using unpaired Student's $t$ test.

**Results**

Intravenous Dose. After an intravenous bolus injection, the plasma concentration-time profiles of SASP in both male and female mice were similar and the data, although limited, could be described by a multieponential equation (fig. 2). SASP was rapidly eliminated from the plasma with an elimination $t_\alpha$ of 0.5 hr in males and 1.2 hr in females. The male mice also had a greater $CL_{tot}$ in comparison with the females (table 1). By 6 hr, no detectable concentrations of parent SASP were found in plasma of mice of either sex (fig. 2). Following intravenous administration of SASP, its metabolite, SP, appeared in plasma and reached a $C_{max}$ at 3 hr (fig. 2). SP was eliminated from plasma more slowly than parent SASP in both sexes ($t_\alpha = 2–5$ hr). The AUC of SP was ~2- to 4-fold higher than that of SASP (table 1). Neither AcSP nor hydroxylated SP metabolites were detected in plasma after intravenous administration of SASP.

Single Oral Dose. Following single oral doses of SASP, detectable concentrations of parent SASP appeared rapidly in plasma at all four doses (fig. 3, 675 mg/kg dose illustrated). The $C_{max}$
values were achieved within 0.5–2 hr of dosing. Thereafter, the concentrations declined rapidly with an elimination \( t_\text{e} \) of 0.9–2.3 hr in both sexes (table 2). \( F \) for SASP was 16.6–18.2% in both sexes at a dose of 67.5 mg/kg. At doses of 675, 1,350, and 2,700 mg/kg, \( F \) varied between 2.6–7.8% in males and 6.7–8.7% in females (table 2). At these three higher doses, \( F \) tended to decrease with an increase in the dose of SASP (table 2, correlation coefficient, \(-0.982\)). Determinations of \( F \) and \( \text{MAT} \) were made with reference to the single intravenous dose experiment that used only one dose (5 mg/kg, iv).

After oral administration of SASP, SP and AcSP were identified in mouse plasma at all four doses (table 2, fig. 3). Both SP and AcSP showed a delayed appearance in plasma (\( T_{\text{max}} \) occurred \( \sim 3–7 \) hr after the \( T_{\text{max}} \) for SASP). SP was present in much higher concentrations (highest \( C_{\text{max}} \) and AUC). In male mice, the AUC of SP was 21- to 32-fold greater than that of SASP at corresponding doses (table 2). However, the AUC of SP did not increase with increasing doses of SASP at doses exceeding 675 mg/kg. AcSP, an acetylated metabolite of SP, had AUC values 1.9- to 2.5-fold higher than those of SASP, but 10- to 13-fold lower than those of SP in male mice (table 2). The apparent \( K \) of SP or AcSP were 2.5- to 6.4-fold lower than those of SASP (table 2). These results indicate that the metabolites were eliminated more slowly than the parent compound (fig. 3). The toxicokinetic properties of SASP, SP, and AcSP in female mice were similar to those obtained in males. It is clear that after a single oral dose of SASP, the metabolites, SP, and AcSP, achieved greater plasma concentrations that were more prolonged than SASP. It is interesting to note that the AUC values of SASP and SP in females, in general, were consistently higher than those seen in males at all four doses (table 2).

Multiple Oral Doses. In the multiple-dose study, animals received daily doses of SASP for three consecutive days. As in the single-dose studies, SASP, SP, and AcSP were found in plasma of both sexes. Multiple dosing in male or female mice did not cause any change in the plasma concentration-time patterns of SASP relative to that seen after a single oral dose. Nor did multiple dosing (at any dose) alter significantly the values of SASP kinetic parameters such as \( C_{\text{max}}, T_{\text{max}}, t_\text{e}, \text{AUC}, \text{MAT}, \) and \( F \).

Multiple dosing with SASP, however, did have a significant impact on the toxicokinetics of SP. For example, at a dose of 1,350 mg/kg, multiple-dose treatment significantly increased the plasma \( C_{\text{max}} \) of SP in male mice as compared with the value achieved after a single oral dose (fig. 4A). Similar increases in the plasma \( C_{\text{max}} \) of SP following multiple dosing were also observed at the other dose levels (675 and 2,700 mg/kg, data not shown), as well as in female mice (fig. 4A). The AUC values of SP were in general greater in the multiple-dose study than in the single-dose study (fig. 4B), although the data did not allow for statistical comparison. Multiple-dose treatment of SASP with all three doses did not increase the plasma \( C_{\text{max}} \) and AUC of AcSP compared with the corresponding single doses, although an increase in those parameters of its precursor, SP, was observed in these same animals (fig. 4). The other potential hydroxylated and/or acetylated metabolite(s) of SP were not detected in plasma of either male or female mice following multiple dosing of SASP.

Gender Differences. A gender-related difference in the toxicokinetic properties of SASP, as well as its metabolite, SP, was observed in this study with both single and multiple doses at all dose levels investigated (figs. 4 and 5). For example, female mice had a higher \( C_{\text{max}} \) of SASP and SP than did male mice when both groups of animals were administered orally 2,700 mg/kg of SASP daily for 3 days (fig. 5). Further analysis of the MAT in both sexes revealed that the MAT in males (4.4 hr) was similar to that in females (3.5 hr), following repeated dosing of 2,700 mg/kg of SASP. Therefore, the absorption of SASP by both sexes seemed to occur at a similar rate. Because the female mice had a smaller \( CL \) (table 1), the higher \( C_{\text{max}} \) and AUC of SASP in female mice might be due to the slower elimination of SASP in this sex. Although the plasma AUC values of SP in female mice were higher than those obtained in males (table 2, fig. 4), the AUC of AcSP in both sexes was approximately the same in either single- or multiple-dose studies at all three doses (table 2, fig. 4).

### TABLE 1

<table>
<thead>
<tr>
<th></th>
<th>MRT ( h )</th>
<th>( t_{\text{e}} ) ( h )</th>
<th>( K ) ( h^{-1} )</th>
<th>AUC ( \mu \text{M} \cdot \text{hr}^{-1} )</th>
<th>( CL ) ( \text{liters/hr-kg}^{-1} )</th>
<th>( V_{\text{p}} ) ( \text{liters/kg} )</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Male</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SASP</td>
<td>0.45</td>
<td>0.54</td>
<td>1.278</td>
<td>9.21</td>
<td>1.36</td>
<td>1.07</td>
</tr>
<tr>
<td>SP</td>
<td>4.60</td>
<td>1.90</td>
<td>0.364</td>
<td>42.20</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Female</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SASP</td>
<td>0.78</td>
<td>1.19</td>
<td>0.581</td>
<td>21.39</td>
<td>0.59</td>
<td>1.01</td>
</tr>
<tr>
<td>SP</td>
<td>8.67</td>
<td>4.80</td>
<td>0.144</td>
<td>52.65</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Mice (22 ± 2 g) were administered an intravenous bolus dose of SASP (5.0 mg/kg). Parameters were computed from AUCs, where each point represents the mean of 4–6 animals.
TABLE 2
Pharmacokinetic parameters of SASP, SP, and AcSP following single oral doses of SASP in B6C3F1, mice

<table>
<thead>
<tr>
<th>Sasp Dose</th>
<th>Compound Analyzed</th>
<th>t&lt;sub&gt;1/2&lt;/sub&gt;</th>
<th>K</th>
<th>AUC</th>
<th>MAT</th>
<th>F</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg/kg</td>
<td>hr</td>
<td>hr&lt;sup&gt;-1&lt;/sup&gt;</td>
<td>µL·hr&lt;sup&gt;-1&lt;/sup&gt;</td>
<td>hr</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>67.5</td>
<td>SasP</td>
<td>0.9</td>
<td>0.802</td>
<td>21</td>
<td>0.43</td>
<td>16.61</td>
</tr>
<tr>
<td></td>
<td>SP</td>
<td>2.2</td>
<td>0.318</td>
<td>430</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AcSP</td>
<td>1.6</td>
<td>0.440</td>
<td>44</td>
<td></td>
<td></td>
</tr>
<tr>
<td>675</td>
<td>SasP</td>
<td>1.7</td>
<td>0.402</td>
<td>97</td>
<td>1.95</td>
<td>7.82</td>
</tr>
<tr>
<td></td>
<td>SP</td>
<td>11.1</td>
<td>0.063</td>
<td>3134</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AcSP</td>
<td>5.8</td>
<td>0.119</td>
<td>239</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1,350</td>
<td>SasP</td>
<td>2.3</td>
<td>0.304</td>
<td>135</td>
<td>2.79</td>
<td>5.44</td>
</tr>
<tr>
<td></td>
<td>SP</td>
<td>7.4</td>
<td>0.094</td>
<td>2995</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AcSP</td>
<td>6.2</td>
<td>0.112</td>
<td>260</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2,700</td>
<td>SasP</td>
<td>1.8</td>
<td>0.379</td>
<td>127</td>
<td>2.40</td>
<td>2.56</td>
</tr>
<tr>
<td></td>
<td>SP</td>
<td>7.3</td>
<td>0.094</td>
<td>2811</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AcSP</td>
<td>10.1</td>
<td>0.068</td>
<td>271</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>SasP</td>
<td>1.3</td>
<td>0.520</td>
<td>52</td>
<td>0.73</td>
<td>18.16</td>
</tr>
<tr>
<td></td>
<td>SP</td>
<td>3.3</td>
<td>0.210</td>
<td>540</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AcSP</td>
<td>3.4</td>
<td>0.206</td>
<td>17</td>
<td></td>
<td></td>
</tr>
<tr>
<td>675</td>
<td>SasP</td>
<td>1.0</td>
<td>0.672</td>
<td>250</td>
<td>0.72</td>
<td>8.66</td>
</tr>
<tr>
<td></td>
<td>SP</td>
<td>7.9</td>
<td>0.088</td>
<td>6261</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AcSP</td>
<td>10.2</td>
<td>0.068</td>
<td>268</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1,350</td>
<td>SasP</td>
<td>1.4</td>
<td>0.483</td>
<td>385</td>
<td>1.20</td>
<td>6.67</td>
</tr>
<tr>
<td></td>
<td>SP</td>
<td>8.3</td>
<td>0.084</td>
<td>3464</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AcSP</td>
<td>8.7</td>
<td>0.080</td>
<td>234</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2,700</td>
<td>SasP</td>
<td>1.7</td>
<td>0.401</td>
<td>845</td>
<td>2.03</td>
<td>7.32</td>
</tr>
<tr>
<td></td>
<td>SP</td>
<td>9.8</td>
<td>0.071</td>
<td>4082</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AcSP</td>
<td>8.3</td>
<td>0.083</td>
<td>224</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Mice (5–7/time point) received SASP in corn oil by oral gavage.

Each point represents the mean of 5–7 animals. Value in parentheses was not used in data analysis.

Discussion

SASP-induced genotoxicities have been observed in both humans and experimental animals (14–17). Although SP is identified (22) and thus suggested as a major metabolite pertinent to the genotoxicity in humans with SASP therapy (14, 15), no information is available on metabolism and toxicokinetics of SASP and its metabolite(s) in B6C3F1 mice. Therefore, in an attempt to interpret further the mechanism by which SASP induces mutagenic damage, the toxicokinetics and metabolism of SASP were studied in male and female B6C3F1, mice.

Following intravenous bolus administration of SASP to mice, the plasma concentrations of SASP declined rapidly in both sexes (table 1). SP was a major metabolite in mouse plasma (fig. 2). The work conducted by Zapp et al. (25) indicates that the liver does not reduce SASP to a great extent after SASP enters the systemic circulation. Hence, the appearance of SP in mouse plasma following an intravenous dose of SASP suggests that the parent SASP must undergo substantial biliary excretion prior to gastrointestinal azo reduction and subsequent absorption of SP. The delayed appearance of SP in the plasma supports this conclusion.

F for SASP following a single oral dose of 67.5 mg/kg varied between 15–18% in both sexes. These values fall in the range of those obtained in humans (F = 10–20% of the oral dose) who received therapeutic doses (2–4 g/day) of SASP [i.e. 40–70 mg/kg of body weight/day (2, 3, 6)]. In contrast, at doses that exceed therapeutic doses, F for SASP appears to decrease (table 2). This dose-related decrease of F probably reflects the very limited aqueous solubility of SASP in the gastrointestinal fluids and the subsequent decrease in absorption efficiency with increasing dose. Hence, the lower F for SASP in mice could be attributed largely to the limited solubility of the compound at the higher doses.

After a single oral dose of SASP, two major metabolites (SP and AcSP) were identified in mouse plasma of both sexes (fig. 3), which is consistent with results from humans (7, 8) and rats (14). The toxicokinetic profile of SP indicates the following characteristics: (1) a delayed T<sub>max</sub> (i.e. C<sub>max</sub> appeared 4–8 hr after

Fig. 3. Concentration-time profiles of SASP and its major metabolites, SP and AcSP, in plasma of male mice, following a single oral dose of SASP (675 mg/kg by gavage in corn oil).

Each point represents the mean of 5–7 animals. Value in parentheses was not used in data analysis.
an F of 75% (26). In healthy human volunteers, SP is detected in the blood 3–5 hr after ingestion of SASP, a time consistent with the transit time of the parent drug to sites of absorption (colon) and where azo bond reduction takes place (22). Therefore, the delayed appearance of SP in B6C3F1 mice following oral administration of SASP is probably related to the movement of the parent compound down the gastrointestinal tract. The appearance of SP in blood could also be affected by, among other factors, the capacity of intestinal bacteria to reduce the azo linkage and the further metabolism of SP.

In the present study, SP had the highest $C_{\text{max}}$ and AUC of the compounds measured. The substantially higher plasma concentrations of SP compared with those of SASP following SASP oral dosing has been reported for humans and other experimental animals (1, 2, 8). Because the elimination rate constant of SP in mice was smaller than that of SASP (table 2) and because SP is better absorbed from the gut than SASP (26), it is reasonable to conclude that the higher plasma concentrations of SP in B6C3F1 mice after a single oral dose of SASP is due to the more efficient absorption and slower clearance of SP in both sexes compared with those processes for SASP.

AcSP appeared in the plasma at times later than SASP. The AUC values of AcSP were much lower than those of SP. This low ratio of AcSP vs. SP might suggest a slow rate of acetylation. The polymorphic acetylation of SP has been verified in humans (22, 27, 28). In those who are classified as slow acetylators, the SP plasma concentrations are significantly higher than those of fast acetylators. The reverse is also true for AcSP; the fast acetylators have higher plasma concentrations of AcSP than do the slow acetylators (29, 30). A study conducted by Astbury and Taggart (29) indicated that the steady-state serum concentrations of unchanged SP were about twice that of AcSP in human subjects with a slow acetylator status. It has also been reported that the incidence of side effects to SASP treatment is higher in slow acetylators than in fast acetylators (30–32). Results of the present study in both male and female mice following a single oral dose of SASP at three doses indicated that the AUC values of SP were ~10- to 23-fold greater than those of AcSP (fig. 4, table 2). It is possible, therefore, that B6C3F1 mice might acetylate SP at a slower rate than humans. Other factors, however, must also be considered when comparing metabolite concentrations such as metabolite elimination clearance.

Repeated dosing of mice with SASP for 3 days did not greatly change the plasma concentration-time profiles of SASP and AcSP in comparison to the single-dose profile. Because SASP was rapidly eliminated from the plasma (table 2, fig. 5), the lack of effect of multiple dosing on the plasma profile of SASP was to be expected and suggests that SASP will not accumulate in the body. In contrast, multiple dosing did affect the SP plasma concentrations. For compounds that accumulate in the body, it is possible to achieve a higher plasma $C_{\text{max}}$ following repeated dosing than following single dosing. In the current study, the plasma $C_{\text{max}}$ of SP after multiple dosing was significantly higher than that after a single dose (fig. 4). Therefore, following multiple dosing with SASP, SP would tend to accumulate in the body.

A distinct and significant gender-dependent difference in the toxicokinetic profiles of both SASP and SP was also observed in the current study. Female mice had higher plasma concentrations of SASP and SP than did the males (fig. 5). Although MATs in males were similar to those in females following oral dosing of SASP (table 2), the $CL_{\text{f}}$ of SASP in males was about twice that in females (table 1). Hence, a slower clearance of SASP in females

**Fig. 4.** Effect of multiple oral dosing with SASP on the plasma $C_{\text{max}}$ and AUC of SASP and its major metabolites in mice.

Mice (both sexes) received either a single oral dose or three daily consecutive doses of SASP at the dose of 1,350 mg/kg. *$p < 0.001$; **$p < 0.05, N = 4–6$.

**Fig. 5.** Plasma concentration-time profiles of SASP and SP in male and female mice who received oral doses of SASP (2,700 mg/kg) once daily for 3 days.

Plasma samples were obtained at the indicated times after the last dose. Each point represents the mean of 5–7 animals.
may account for the higher plasma SASP concentrations in this sex. Because we did not observe any difference in AcSP plasma profiles between the two sexes, the higher SP plasma concentrations in females does not seem to be related to a difference in the rate of acetylation of SP.

SP has been regarded as a candidate responsible for the toxicities associated with SASP therapy. Examples of these toxicities include bone marrow depression and anemia (3, 28). Strong evidence indicates that the increases in the frequency of SCE and MN in patients taking SASP for inflammatory bowel disease are caused by the drug per se and not by the disease (14, 15). The dose of SASP and the length of treatment period determine, to a large extent, the magnitude of these indicators of genotoxicity.

In addition, patients of slow acetylator status appear to have a greater SCE than fast acetylators (14, 15). Taken together, these results from human studies suggest that the chromosome-damaging effects of SASP therapy may be partially mediated through SP and/or some other metabolites. Although the exact molecular form(s) responsible for the genotoxicity caused by SASP treatment is still unknown at present, the high SP plasma concentrations resulting from SASP administration in B6C3F1 mice, supports the assumption that SP and/or its metabolite(s) may be related to the mutagenicity observed in B6C3F1 mice and in humans as well.

In conclusion, SASP was rapidly but poorly absorbed after oral dosing. The percentage of the dose absorbed was <10% at doses of 675 mg/kg and above in both sexes. Following oral administration of SASP, SP and AcSP were identified in mouse plasma. The efficient absorption and slow elimination of SP by both sexes contribute to its higher plasma concentration-time profiles. The elimination of the parent SASP appears gender-dependent. The low plasma concentrations of AcSP and a large ratio of AUCSP to AUCAcSP may suggest a slow acetylation of SP by B6C3F1 mice.

Acknowledgments. We gratefully acknowledge the technical assistance of Mrs. Margaret J. Kattnig.

References
27. H. Schroder and D. A. P. Evans: The polymorphic acetylation of sulphasalazine therapy and the...


